TREACE MEDICAL CONCEPTS, INC.
For the period ended Dec 31, 2025. Filed Feb 27, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 27, 2026
TMCI$4.03-3.6%Stored close · as of Nov 6, 2026
Contents
Balance Sheets
(in thousands, except share and per share amounts)
| December 31, | December 31, | |
|---|---|---|
| 2025 | 2024 | |
| Assets | ||
| Current assets | ||
| Cash and cash equivalents | $10,708 | $11,350 |
| Marketable securities, short-term | 37,659 | 64,327 |
| Accounts receivable, net of allowance for credit losses of $1,824 and $1,326 as of December 31, 2025 and December 31, 2024, respectively | 42,155 | 40,803 |
| Inventories | 36,031 | 39,255 |
| Prepaid expenses and other current assets | 5,501 | 5,667 |
| Total current assets | 132,054 | 161,402 |
| Property and equipment, net | 29,752 | 25,953 |
| Intangible assets, net of accumulated amortization of $2,375 and $1,425 as of December 31, 2025 and December 31, 2024, respectively | 7,125 | 8,075 |
| Goodwill | 12,815 | 12,815 |
| Operating lease right-of-use assets | 7,614 | 8,442 |
| Other non-current assets, net of allowance for credit losses of $69 and $69 as of December 31, 2025 and December 31, 2024, respectively | 1,221 | 407 |
| Total assets | $190,581 | $217,094 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities | ||
| Accounts payable | $6,726 | $10,522 |
| Accrued liabilities | 5,784 | 7,197 |
| Accrued commissions | 9,365 | 10,121 |
| Accrued compensation | 6,331 | 6,575 |
| Other liabilities | 2,429 | 510 |
| Total current liabilities | 30,635 | 34,925 |
| Long-term debt, net | 55,583 | 53,306 |
| Operating lease liabilities, net of current portion | 13,982 | 15,934 |
| Other long-term liabilities | 3,049 | 37 |
| Total liabilities | 103,249 | 104,202 |
| Commitments and contingencies (Note 8) | ||
| Stockholders’ equity | ||
| Preferred stock, $0.001 par value, 5,000,000 shares authorized as of December 31, 2025 and December 31, 2024; 0 shares issued as of December 31, 2025 and December 31, 2024 | — | — |
| Common stock, $0.001 par value, 300,000,000 shares authorized; 64,029,378 and 62,385,101 shares issued as of December 31, 2025 and December 31, 2024, respectively | 64 | 62 |
| Additional paid-in capital | 337,371 | 303,004 |
| Accumulated deficit | (248,992) | (189,990) |
| Accumulated other comprehensive income (loss) | 72 | 97 |
| Treasury stock, at cost; 165,513 and 23,391 shares as of December 31, 2025 and December 31, 2024, respectively | (1,183) | (281) |
| Total stockholders’ equity | 87,332 | 112,892 |
| Total liabilities and stockholders’ equity | $190,581 | $217,094 |
PTreace Medical Concepts, Inc.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.